Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome

Advances in Hematology

Volumn 2010, Issue , 2010, Pages

  Leitch, Heather A ^a   Badawi, Maha A ^a   Vickars, Linda M ^a   Chase, Jocelyn M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE; FERRITIN; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOPENIA; DISEASE COURSE; DRUG DOSE TITRATION; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IRON CHELATION; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SKIN BIOPSY; SKIN DEFECT;

EID: 77953441332     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2010/164045     Document Type: Article

References (44)

1. Greenberg P., Cox C., LeBeau M. M., International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 1997 89 6 2079 2088 (Pubitemid 27132124)
2. Schiffer C. A., Clinical issues in the management of patients with myelodysplasia Hematology 2006 205 210
3. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life British Journal of Haematology 2003 120 6 1037 1046 (Pubitemid 36411563)
4. Kantarjlan H., Issa J.-P. J., Rosenfeld C. S., Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 2006 106 8 1794 1803
5. List A., Kurtin S., Roe D. J., Efficacy of lenalidomide in myelodysplastic syndromes New England Journal of Medicine 2005 352 6 549 557 (Pubitemid 40204668)
6. Raza A., Meyer P., Dutt D., Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes Blood 2001 98 4 958 965
7. Silverman L. R., Demakos E. P., Peterson B. L., Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B Journal of Clinical Oncology 2002 20 10 2429 2440 (Pubitemid 34525728)
8. Porter J. B., Practical management of iron overload British Journal of Haematology 2001 115 2 239 252
9. Malcovati L., Della Porta M. G., Pascutto C., Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making Journal of Clinical Oncology 2005 23 30 7594 7603 (Pubitemid 46291823)
10. Malcovati L., Germing U., Kuendgen A., Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes Journal of Clinical Oncology 2007 25 23 3503 3510 (Pubitemid 47315575)
11. Olivieri N. F., Nathan D. G., Macmillan J. H., Survival in medically treated patients with homozygous -thalassemia New England Journal of Medicine 1994 331 9 574 578 (Pubitemid 24265699)
12. Leitch H. A., Leger C. S., Goodman T. A., Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy Clinical Leukemia 2008 2 3 205 211
13. Gattermann N., Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload International Journal of Hematology 2008 88 1 24 29
14. Bennett J. M., Consensus statement on iron overload in myelodysplastic syndromes American Journal of Hematology 2008 83 11 858 861
15. Bennett J. M., Catovsky D., Daniel M. T., Proposals for the classification of the myelodysplastic syndromes British Journal of Haematology 1982 51 2 189 199 (Pubitemid 12073508)
16. Vardiman J. W., Harris N. L., Brunning R. D., The World Health Organization (WHO) classification of the myeloid neoplasms Blood 2002 100 7 2292 2302
17. Del Ro Garma J., Fernandez L. C., Fonrodona B. F. J., Desferrioxamine in the treatment of myelodysplastic syndromes Haematologica 1997 82 5 639 640
18. Jensen P. D., Heickendorff L., Pedersen B., The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload British Journal of Haematology 1996 94 2 288 299 (Pubitemid 26247987)
19. Messa E., Cilloni D., Messa F., Arruga F., Roetto A., Saglio G., Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis Acta Haematologica 2008 120 2 70 74
20. Jensen P. D., Jensen I. M., Ellegaard J., Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome British Journal of Haematology 1992 80 1 121 124
21. Angelucci E., Turlin B., Canatan D., Iron chelation therapy with deferasirox (Exjade, ICL670) or deferoxaimine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis Blood 2005 106 11 757a
22. Brittenham G. M., Griffith P. M., Nienhuis A. W., Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major New England Journal of Medicine 1994 331 9 567 573
23. Davis B. A., Porter J. B., Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk -thalassemia Blood 2000 95 4 1229 1236
24. Olivieri N. F., Brittenham G. M., Iron-chelating therapy and the treatment of thalassemia Blood 1997 89 3 739 761
25. Rose C., Brechignac S., Vassilief D., Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM Blood 2007 110 11 80 81a
26. Marsh J. H., Hundert M., Schulman P., Deferoxamine-induced restoration of haematopoiesis in myelofibrosis secondary to myelodysplasia British Journal of Haematology 1990 76 1 148 149 (Pubitemid 20326810)
27. Breuer W., Shvartsman M., Cabantchik Z. I., Intracellular labile iron International Journal of Biochemistry and Cell Biology 2008 40 3 350 354 (Pubitemid 351241220)
28. Britton R. S., Leicester K. L., Bacon B. R., Iron toxicity and chelation therapy International Journal of Hematology 2002 76 3 219 228
29. Smeets M. E., Vreugdenhil G., Holdrinet R. S., Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis American Journal of Hematology 1996 51 3 243 244
30. Di Tucci A. A., Murru R., Alberti D., Rabault B., Deplano S., Angelucci E., Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670) European Journal of Haematology 2007 78 6 540 542 (Pubitemid 46753589)
31. Park S.-J., Han C.-W., Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis Journal of Korean Medical Science 2008 23 2 320 323
32. Hartmann J., Sinzig U., Wulf G., Evidence for a suppression of the colony forming capacity of erythroid progenitors by iron overload in patients with MDS Blood 2008 11 932a
33. Anderson L. J., Westwood M. A., Holden S., Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2 cardiovascular magnetic resonance British Journal of Haematology 2004 127 3 348 355 (Pubitemid 39468951)
34. Anderson G. J., Mechanisms of iron loading and toxicity American Journal of Hematology 2007 82 12, supplement 1128 1131
35. Amer J., Fibach E., Oxidative status of platelets in normal and thalassemic blood Thrombosis and Haemostasis 2004 92 5 1052 1059 (Pubitemid 39545529)
36. Amer J., Goldfarb A., Fibach E., Flow cytometric analysis of the oxidative status of normal and thalassemic red blood cells Cytometry A 2004 60 1 73 80 (Pubitemid 38859203)
37. Esposito B. P., Breuer W., Sirankapracha P., Pootrakul P., Hershko C., Cabantchik Z. I., Labile plasma iron in iron overload: redox activity and susceptibility to chelation Blood 2003 102 7 2670 2677 (Pubitemid 37193611)
38. Rachmilewitz E., Merkel D., Ghoti H., Improvement of oxidative stress parameters in MDS patients with iron overload treated with deferasirox Blood 2008 112 11 A924 A925
39. Chan L. S. A., Buckstein R., Reis M. D., Iron overload and haematopoiesis in MDS: does blood transfusion promote progression to AML? Blood 2008 112 11 928a
40. Szuber N., Buss J. L., Soe-Lin S., Alternative treatment paradigm for thalassemia using iron chelators Experimental Hematology 2008 36 7 773 785
41. List A. F., Baer M. R., Steensma D., Deferasirox (ICL670); Exjade) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS) Blood 2008 112 11 523a
42. Ren X., Dorrington K. L., Maxwell P. H., Robbins P. A., Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans Journal of Applied Physiology 2000 89 2 680 686 (Pubitemid 30637118)
43. Messa E., Defilippi I., Roetto A., Deferasirox is the only iron chelator acting as a potent NFKB inhibitor in myelodysplastic syndromes Blood 2008 112 11 923a
44. Sloand E. M., Mainwaring L., Fuhrer M., Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome Blood 2005 106 3 841 851 (Pubitemid 41076423)